"Medicine points" of the two sessions: these 15 medicine tycoons say what you want

This year's government work report of the NPC and CPPCC pointed out that we need to reform and improve the policy of combining medical care with maintenance, reduce and unify the starting line of serious illness insurance, develop biomedicine, and innovate traditional Chinese medicine As a representative of the National People's Congress and a member of the CPPCC, pharmaceutical entrepreneurs gathered together to make suggestions and suggestions for the development of the pharmaceutical industry Minai.com selected the advice of 15 pharmaceutical tycoons, including auxiliary drugs, volume purchase, consistency evaluation Did they say what you thought? Ding Liming: it is suggested to give priority to purchasing with volume to the representative of the National People's Congress of the people's Republic of China and the chairman and CEO of Beida Pharmaceutical Co., Ltd Ding Liming said that while the level of independent drug innovation in China is improving, it is also faced with many problems, especially after the product is put on the market, due to the difficulty of market access, it is difficult to apply it on a large scale nationwide Therefore, he suggested that in the national drug centralized procurement, we should strengthen the support for independent innovative drugs, establish a linkage mechanism between the national drug centralized procurement and the national medical insurance negotiation, and give priority to the inclusion of domestic innovative drugs in the procurement, especially the domestic innovative drugs that have passed the national drug price negotiation and entered the national medical insurance catalogue, and purchase at the medical insurance negotiation price, and fully High or high proportion of reimbursement, promote domestic innovative drugs to benefit Chinese patients as soon as possible Ding Liming also said that the "4 + 7" centralized procurement pilot adopted the exclusive bid winning method In the investigation, it was also learned that the bid winning of a single variety has reduced the market expectation of many enterprises that are carrying out or are about to carry out the conformity evaluation of generic drugs, which has a certain impact on their enthusiasm to promote the conformity evaluation Therefore, it is suggested to further optimize the national centralized procurement system, determine the reasonable bid price through competitive bidding, and adopt the mode of multi variety bid winning Du Zhenxin: we should strictly control auxiliary drugs and promote scientific drug use Du Zhenxin, deputy to the National People's Congress and chairman of Chenxin Pharmaceutical Co., Ltd., believes that "we should understand and use auxiliary drugs in a scientific way, and we should not do everything in one way." Some so-called auxiliary drugs have different functions and meanings under different conditions of use in different diseases They are auxiliary in some departments or disease treatment, while in other diseases treatment may be clinical demand type therapeutic drugs For example, omeprazole, some departments are auxiliary drugs, but in the digestive department is commonly used therapeutic drugs Many adjuvant drugs are not dispensable, but play an important role in the treatment of major diseases, such as supplementing essential substances, reducing the adverse reactions of the main drugs, immune regulation, improving the quality of life and so on Without these adjuvants, the whole treatment scheme will fail, bring serious adverse reactions, or make patients suffer from great disease pain, or even death Du Zhenxin suggested that the state promote rational, standardized and scientific drug use We should start from the following aspects: first, we should strengthen the management of clinical pathway and design clinical pathway scientifically; second, we should continue to promote the payment by disease and expand the scope of payment by disease; third, we should establish the corresponding database to track and analyze the use status and effect of some products and Medicare drugs with a large amount of medication through big data; fourth, we should play the role of medical insurance and strictly restrict the use of auxiliary drugs Fifth, for auxiliary drugs with complex ingredients, large adverse reactions and uncertain efficacy, they are directly deleted from the medical insurance catalog and the basic drug catalog Li Yan: Li Yan, deputy of the National People's Congress and President of Qilu Pharmaceutical Co., Ltd., who included the evaluation of clinical research development ability in the evaluation of medical institutions, said that she had brought suggestions to include the evaluation of clinical research development ability in the evaluation of medical institutions First, led by the national health and Health Commission and relevant departments, a survey was conducted on the national medical institutions, especially the affiliated hospitals of universities According to the survey results, we will increase the investment in clinical research management funds and personnel, set up independent and full-time clinical research management departments, and carry out the management of clinical research affairs The second is to establish an independent evaluation and assessment system for medical institutions carrying out clinical trials, systematically and systematically including the quantity and quality of clinical trials such as new drugs and new medical devices, as well as the quantity of clinical studies initiated by researchers and the evaluation of research output into the level evaluation of medical institutions The third is to strengthen the hierarchical management of the ethics committee, and take the review ability and efficiency of the ethics committee as one of the evaluation indicators of the medical institutions' level review Fourth, improve the scientific research design level and scientific research literacy of clinical medical personnel Fifth, encourage medical staff to actively carry out and participate in all kinds of clinical research, and further improve the innovation environment of medical staff Geng Funeng: Geng Funeng, deputy to the National People's Congress of the great health industry of medicine and chairman of gooddoctor Pharmaceutical Group, said that this year's two sessions mainly focus on two aspects, the first of which is intellectual property protection "Good doctor" has more than 300 patents, which will eventually be converted into the market, and the market can only be converted through the brand When a brand gets a return, there will be people who are not willing to work to infringe Only by strengthening the protection of the ecological chain of intellectual property, can the enterprise develop healthily In addition, the pharmaceutical industry has been developing rapidly over the years After the economic development, people's demand for health has increased, such as the demand for beauty, health care and other aspects of medical care The plan of a good doctor's medicine industry is to do a good job in the big health industry of medicine As long as we are down-to-earth, it will be spring at any time Hu Jiqiang: to establish a coordination mechanism to promote the development of traditional Chinese medicine, Hu Jiqiang, deputy to the National People's Congress and chairman of Kangenbei Group Co., Ltd., mentioned the following six suggestions in the proposal on establishing a coordination mechanism at the level of the State Council to promote the development of traditional Chinese Medicine: First, establish a coordination mechanism at the level of the State Council Under the framework of "one law, one outline and two plans", put forward the "top-level design of traditional Chinese Medicine Inheritance and development", reasonably allocate the functions of departments involved in the whole industry chain management of traditional Chinese medicine, minimize the regulatory gap and inefficiency brought by "Jiulong water treatment", and improve the coordination and scientificity of supervision Second, we should urge the State Administration of traditional Chinese medicine to perform its statutory duties in charge of the work of traditional Chinese medicine, give it full authorization to carry out relevant work in accordance with the law of traditional Chinese medicine, and establish the "leading group for the development of traditional Chinese medicine under the State Council" if necessary Third, urge the health and Health Commission and the Chinese medicine bureau to truly implement the national policy of "attaching equal importance to both traditional and Western medicine", fully understand the clinical value of traditional Chinese medicine, promote the establishment of clinical pathway of traditional Chinese medicine, strengthen the management of rational use of drugs, and correct the rough treatment of traditional Chinese medicine Fourth, urge the State Food and drug administration to study and formulate the review and approval system of traditional Chinese medicine in line with the characteristics of traditional Chinese medicine as soon as possible, incorporate the formulation of the administrative measures for registration of traditional Chinese medicine into the revision plan, and start the re evaluation work after the listing of traditional Chinese medicine Fifthly, we need to urge the market supervision bureau to take the lead, coordinate the Ministry of agriculture and rural areas, the Ministry of Commerce, the Ministry of natural resources, the Ministry of industry and information technology, the forestry and grassland Bureau, the drug administration, the Chinese medicine bureau, the health and Health Committee and other departments to carry out the work of "rectifying the production, circulation and use of traditional Chinese medicine", form a long-term mechanism, and effectively guarantee the quality, safety and efficacy of traditional Chinese medicine from the source Sixth, March 17 will be designated as the traditional Chinese medicine Festival At the same time, we will strengthen the publicity and promotion of traditional Chinese medicine culture, and enhance the Chinese people's confidence in traditional Chinese medicine culture Only when Chinese medicine goes out of the country can we have the foundation Xiao Wei: it is suggested that Xiao Wei, the representative of the National People's Congress and the chairman and Secretary of the Party committee of Jiangsu Kangyuan Group Co., Ltd., promote the registration and reform of new Chinese medicine as soon as possible In recent years, the development of traditional Chinese medicine industry is rapid, and the issues related to traditional Chinese medicine have also become the focus of heated discussion among the representatives and members of the pharmaceutical industry of the two sessions Xiao Wei said that the high-quality development of traditional Chinese medicine industry should be promoted so that the innovative achievements of traditional Chinese medicine can benefit the masses faster and better Xiao Wei suggested that the SDA should organize experts in the traditional Chinese medicine industry, R & D units and enterprises with enthusiasm for the innovation of traditional Chinese medicine as soon as possible to clarify the development context of the innovation of traditional Chinese medicine, and study and formulate a series of reform systems and methods for the review and approval of traditional Chinese medicine that meet the strategic needs of the inheritance and innovation of traditional Chinese medicine Among them, we should fully consider the characteristics of traditional Chinese medicine, clearly define the clinical value of traditional Chinese medicine from the comprehensive role of disease, pharmacoeconomics and other aspects, and comprehensively consider its "advantages" from the main efficacy indicators, symptom improvement, recurrence reduction, efficiency and toxicity reduction, treatment cost and other aspects, rather than simply from the "advantages" to carry out the clinical value of new traditional Chinese medicine Value evaluation At the same time, it is necessary to work with the State Administration of traditional Chinese medicine to demonstrate and work out as soon as possible a number of catalogues of dominant diseases of traditional Chinese medicine, formulate policies and give priority to support, such as giving priority to review, speeding up review and reducing the number of clinical verification cases, etc., encourage the research and development of innovative traditional Chinese medicine in major and difficult diseases, chronic diseases, old-age diseases, viral diseases and other advantageous areas of traditional Chinese medicine, so as to research and develop new traditional Chinese medicine We should specify the direction and avoid repeated R & D and low-level R & D Adjust and clarify the classification of new traditional Chinese medicine as soon as possible, further improve the technical requirements of new traditional Chinese medicine, and clearly distinguish the level and level of innovation Xu Jingren: the consistency evaluation of generic drugs is the threshold of competition among pharmaceutical enterprises Xu Jingren, deputy to the National People's Congress and Secretary of the Party committee and chairman of the board of directors of Yangtze River Pharmaceutical Group, believes that in the future competition of generic drugs market, the access threshold is to pass the consistency evaluation, and the price of products is the key to win or lose Xu Jingren said that the challenges faced by Yangzijiang pharmaceutical industry in the future in generic drug market competition are severe "First of all, there is a great pressure for the group to comprehensively pass the consistency evaluation; Yangtze River calendar focuses on huge investment in product production and quality, so the production cost is relatively high, and the price advantage is not obvious in the competition with small-scale enterprises At the same time, he said, "there are opportunities for the development of the Yangtze River The consistency evaluation of generic drugs carried out by the state is completely consistent with the culture of focusing on quality construction of enterprises for a long time, and has really achieved the effect of resonance with the national strategy " Zhao Chao, deputy of the National People's Congress and President of step pharmaceutical The two sessions are in full swing Zhao Chao, President of step pharmaceutical, who has been elected as the deputy of the National People's Congress for three consecutive sessions, has brought new thinking and new suggestions with the times after last year's proposal to speed up the innovation of science and technology of traditional Chinese medicine and increase the support of "going out" of traditional Chinese medicine He called for the construction of a national Integrated Research Institute of brain and heart treatment of traditional Chinese medicine and investment in intelligence We should cultivate talents and enhance innovation ability, and take the new mode of development of Chinese medicine industry supported by Internet plus big data He suggested that the national health and Health Commission should build a large platform of national brain heart CO treatment research institute, under the guidance of the theory of brain heart CO treatment of traditional Chinese medicine, guided by the innovation and industrialization of the prevention and treatment of chronic diseases such as cardiovascular disease, diabetes and complications, and based on the brain heart CO treatment research institute and brain heart CO treatment research center of Zhejiang University of traditional Chinese medicine, the state should build a comprehensive advantage resource allocation, optimization technology and regulation It is a large platform of brain heart Tongzhi Research Institute with complete supporting facilities, complete functions, advanced technical means, integration, independent innovation and close connection Chen Baohua: strict standards to accelerate the consistency evaluation of generic drugs